Recombinant interferon-alfa (Intron A, Roferon-A) has been under investigation as a therapeutic agent for non-Hodgkin’s lymphoma (NHL) for 25 years. It has antitumor efficacy in a number of histologic subtypes but has not
Richard Smalley, MD
Advertisement
Articles by Richard Smalley, MD
Advertisement
Latest Updated Articles
- Role of Interferon-Alfa in NHL: Still Controversial?
Published: August 1st 1999 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Novel SSTR-Targeted Alpha Therapy Shows “Encouraging” Activity in GEP-NETs
2
Pembrolizumab Combo Does Not Significantly Improve OS in Unresectable HCC
3
Radiotherapy Plus Chemoimmunotherapy Improves Frontline ES-SCLC Prognosis
4
Durvalumab Plus Concurrent CRT Does Not Add Benefit in Stage III NSCLC
5
